Consecutive patients who had received at least 1 DES for stable coronary artery disease or acute coronary syndrome at Samsung Medical Center Background-The use of dual-antiplatelet therapy (DAPT) exceeding 12 months may increase a bleeding risk despite a lower risk of ischemic events. There is no study to compare clinical outcomes in patients treated with a single-antiplatelet drug after DAPT in the era of drug-eluting stents (DES). We sought to investigate the efficacy and safety of clopidogrel versus aspirin monotherapy after 12-month DAPT after DES implantation using an institutional registry. Methods and Results-This observational study was conducted on consecutive patients receiving DES between January 2003 and December 2010. A total of 3243 patients receiving 12-month DAPT after DES implantation without adverse clinical outcomes were divided into 2 groups based on prescribed antiplatelet status: aspirin (n=2472) and clopidogrel (n=771). Clinical, angiographic, and procedural characteristics revealed more comorbidities and more complex lesions in the clopidogrel group than in the aspirin group. At 36 months after initiation of antiplatelet monotherapy, clopidogrel was associated with a reduction in risk for a composite of cardiac death, myocardial infarction, or stroke (aspirin versus clopidogrel; 3.8% versus 2.6%; hazard ratio, 0.54; 95% confidence interval, 0.32-0.92; P=0.02). Patients were eligible for the present analysis if they had not had a death, MI, stroke, repeat revascularization, or thrombolysis in MI (TIMI) major bleeding at the 12-month follow-up after the index procedure. Patients were excluded if they received DAPT, warfarin, or antiplatelet therapy other than aspirin or clopidogrel subsequent to the 12-month follow-up after the index procedure. Samsung Medical Center Institutional Review Board approved this study and waived the requirement for written informed consent for access to an institutional PCI registry.
D ual-antiplatelet therapy (DAPT) with aspirin and a P2Y
receptor inhibitor is required to prevent thrombotic complications in all patients receiving drug-eluting stents (DES). 1, 2 However, optimal duration of DAPT after DES implantation remains controversial. Several randomized controlled trials failed to show any benefit of long-term DAPT (≥12 months) versus short-term DAPT. [3] [4] [5] [6] [7] [8] [9] Conversely, an increased risk for bleeding events was observed in patients treated with DAPT >12 months. 5, 6 Recently, the DAPT trials showed that extending DAPT reduced rates of stent thrombosis and myocardial infarction (MI) with an associated increase in moderate bleeding. 10 Although some patients may benefit from extending DAPT beyond 12 months, potential harm in terms of increased bleeding risk should not be overlooked in the DAPT study. Although the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed the superiority of clopidogrel over aspirin in the pre-DES era, 11 aspirin has been the mainstay of treatment for secondary prevention of recurrent ischemic events in patients with atherosclerotic vascular diseases. To date, no study has compared clopidogrel monotherapy with aspirin monotherapy in patients undergoing DES implantation. Therefore, we sought to compare the efficacy and safety of clopidogrel versus aspirin monotherapy after 12-month DAPT in patients undergoing percutaneous coronary intervention (PCI) with DES.
Data Collection
Clinical, procedural, and outcome data were recorded prospectively in our dedicated PCI registry by independent research personnel. Patients were followed up at 1, 6, and 12 months after their index procedure and annually thereafter. Additional information was obtained by telephone contact or medical records of other hospitals if necessary. Adherence to antiplatelet medication was routinely assessed at each time of follow-up. To identify the status of antiplatelet therapy at the unscheduled follow-up, the date and duration of prescribed antiplatelet agents were obtained from the electronic prescribing system at Samsung Medical Center. Follow-up was considered complete if the mortality was confirmed from the National Population Registry of the Korea National Statistical Office using a unique personal identification number or if the patient was successfully contacted at the scheduled follow-up interval. We considered patients to be treated with clopidogrel when this medication was prescribed. Adherence to aspirin was determined from prescribed list and from asking whether patients were regular aspirin user.
Treatment Group
Landmark analysis was performed to classify patients into treatment groups based on 12-month antiplatelet treatment after their index procedure and evaluate the prognosis from this landmark time point. 12 Decisions on the choice of antiplatelet monotherapy were left to the attending physician's discretion. Patients who were event free at their 12-month follow-up were divided into either the aspirin group or the clopidogrel group. When classifying these, a window of 90 days before and after the 12-month follow-up was accepted because of potential time variation in the follow-up process.
Outcomes
Clinical outcomes were measured as the time-to-event data, with subjects being censored beyond 36 months after initiation of antiplatelet monotherapy. The primary efficacy end point was a composite of cardiac death, MI, or stroke. The secondary end points included death from any cause, cardiac death, MI, stroke, stent thrombosis, and a composite of cardiac death or MI. All deaths were considered cardiac unless a definite noncardiac cause could be established. MI was defined as elevated cardiac enzymes (troponin or myocardial band fraction of creatine kinase) with ischemic symptoms or electrocardiography findings indicative of ischemia that were not related to the index procedure. Stroke, as detected by the occurrence of a new neurological deficit, was confirmed by a neurologist and imaging. Definite or probable stent thrombosis was assessed in accordance with the definitions of the Academic Research Consortium. 13 The primary safety end point was major bleeding at 36 months after initiation of antiplatelet monotherapy, as defined according to the TIMI definition.
14 Bleeding was also assessed according to the Bleeding Academic Research Consortium (BARC) criteria. 15 All end points were identified by the attending physicians, and reviewed by 2 authors (T.K.P. and Y.B.S.) who had full access to the patient's clinical and laboratory records. Complicated cases were discussed and adjudicated with 2 other authors (S.H.L. and H.-C.G).
Statistical Analysis
Categorical variables were summarized as frequencies with percentages and were compared using the χ 2 test or Fisher exact test. Continuous variables were presented as median (25th-75th percentiles) and were compared using the Mann-Whitney U test. To reduce the impact of treatment selection bias and potential confounding in this observational study, we adjusted for differences in baseline characteristics by weighted Cox proportional hazards regression models using the inverse probability of treatment weighting (IPTW). 16 The propensity score is the probability given the baseline variable that any patient would be selected for clopidogrel monotherapy. All propensity scores were estimated without regard to outcomes by multiple logistic regression analysis. Stabilized weights for patients with clopidogrel monotherapy were the product of marginal probability for clopidogrel monotherapy and the inverse of propensity score, and stabilized weights for patients with aspirin monotherapy were the product of marginal probability for aspirin monotherapy and the inverse of (1 propensity score). Variables were considered as balanced between aspirin and clopidogrel groups after IPTW adjustment if the standardized mean difference of each variable was <10%. 17 Adjusted survival curves were constructed using IPTW-adjusted Kaplan-Meier estimates at time to first event. 18 The adjustment (IPTW) was further augmented by multiple Cox regression analyses (IPTW+multivariable) with clinical relevant variables including age, sex, diabetes mellitus, chronic kidney disease, previous MI, type of drug-eluting stent, PCI year, and DAPT duration.
The effects of interaction terms between subgroups and treatment effects on clinical outcomes were estimated in the weighted Cox regression model using the IPTW method. For subgroup analyses, a new IPTW was calculated in each subgroup and the adjusted hazard ratio (HR) were estimated using the Cox regression models adjusted by the IPTW. All tests were 2 tailed, and P<0.05 was considered significant. R software version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria, 2015) was used for statistical analysis.
Results

Patients Characteristics
Between January 2003 and December 2010, 4759 patients underwent PCI with DES at the Samsung Medical Center. We excluded 89 patients with incomplete follow-up on
WHAT IS KNOWN
• Long-term dual-antiplatelet therapy demonstrated the thrombotic benefit, but increased in major bleeding events.
• There is no study to compare clinical outcomes in patients treated with a single-antiplatelet drug after dual-antiplatelet therapy in the era of drug-eluting stents.
WHAT THE STUDY ADDS
• When compared with aspirin monotherapy, clopidogrel monotherapy reduced the risk for the composite of cardiac death, myocardial infarction, or stroke at 36 months after initiation of antiplatelet monotherapy in patients who received 12-month dual-antiplatelet therapy after implantation of drug-eluting stents without major adverse cardiac cerebrovascular events.
• Thrombolysis in myocardial infarction major bleeding occurred similarly between the aspirin and clopidogrel groups.
• The benefit of clopidogrel in reducing ischemic outcomes should be tested in future randomized controlled trials.
clinical outcomes within 12 months. We also excluded 665 patients with events until the 12-month follow-up after the index procedure caused by death in 214 patients, non-fatal MI in 57 patients, stroke in 27 patients, repeat revascularization in 349 patients, and TIMI major bleeding in 18 patients. We also excluded 672 patients who received DAPT and 90 patients who received warfarin or an antiplatelet therapy other than aspirin or clopidogrel over the 12-month followup after the index procedure. Of the 3243 patients remaining, 2472 patients received aspirin monotherapy and 771 patients received clopidogrel monotherapy ( Figure 1) .
The baseline clinical characteristics between the 2 groups are shown in Table 1 . The clopidogrel group had a higher prevalence of old age, diabetes mellitus, hypertension, dyslipidemia, current smoking, chronic kidney disease, previous PCI, and previous stroke than the aspirin group. ST-segmentelevation MIs were more prevalent in the aspirin group, whereas unstable angina/non-ST-segment-elevation MIs were more prevalent in the clopidogrel group. Lesion and procedural characteristics are shown in Table 2 . The clopidogrel group had a higher prevalence of multivessel disease. More and longer stents were implanted in the clopidogrel group than in the aspirin group. Sirolimus or paclitaxeleluting stents were implanted more frequently in the aspirin group, whereas everolimus, zotarolimus, or biolimus-eluting stents were implanted more frequently in the clopidogrel group. There were significant differences of PCI year and DAPT duration in the selection of antiplatelet monotherapy. The adherence rates to study medication were similar between 2 groups (Table 3) . After IPTW adjustment of the baseline characteristics, there were no significant differences in baseline covariates between 2 groups except for PCI year and DAPT duration (Tables 1-3) .
Study Outcomes
Follow-up data were available for 100% (3209 of 3209), 100% (3166 of 3166), and 95.4% (2984 of 3128) of the eligible patients at 12, 24, and 36 months after initiation of antiplatelet monotherapy, respectively (Figure 1 ). Observed clinical outcomes at 36-month follow-up after initiation of antiplatelet monotherapy are shown in Table 4 . The primary efficacy end point of cardiac death, MI, or stroke occurred in 95 patients including 35 cardiac deaths, 31 MIs, and 41 strokes in the aspirin group and 20 patients including 4 cardiac deaths, 8 MIs, and 9 strokes in the clopidogrel group. In the weighted Cox proportional hazards regression models using the IPTW method, the risk of primary efficacy end point was significantly lower for the clopidogrel group than for the aspirin group (aspirin versus clopidogrel, 3.8% versus 2.6%; HR, 0.60; 95% confidence interval [CI], 0.36-0.99; P=0.045; Figure 2A ). The risk of stent thrombosis was lower and similar in both groups (0.4% versus 0.3%; HR, 0.40; 95% CI, 0.06-2.44; P=0.32). When the IPTW adjustment was further augmented by multivariable analyses, clopidogrel was associated with a risk reduction for primary efficacy end point (HR, 0.54; 95% CI, 0.32-0.92; P=0.02). The risk of cardiac death was lower with clopidogrel monotherapy than with aspirin monotherapy (1.4% versus 0.5%; HR, 0.31; 95% CI, 0.11-0.93; P=0.04). The results of IPTW-weighted Cox regression analyses for device-oriented end points were presented in Table I in the Data Supplement. The primary safety end point of TIMI major bleeding occurred similarly between both groups (0.9% versus 1.3%; HR, 1.51; 95% CI, 0.76-3.03; P=0.24; Figure 2B ). Fatal bleeding and intracranial bleeding occurred with similar low frequencies. The risk of BARC type 3 or 5 bleeding was similar between both groups. Gastrointestinal bleeding was the most common cause of BARC type 3 or 5 bleeding, but the risk of gastrointestinal bleeding did not differ significantly between the aspirin and the clopidogrel groups.
Subgroup Analysis
The rate of primary efficacy end point was consistently lower trend in the clopidogrel group than in the aspirin group across several subgroups, regardless of age, acute coronary syndrome, diabetes mellitus, current smoking, previous stroke, multivessel disease, stent type, and PCI year (Figure 3 ). There were no significant interactions between several subgroups and primary efficacy end point. Data are median (25th-75th percentiles) or number of patients (%). IPTW indicates inverse probability of treatment weighting; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; SMD, standardized mean difference; STEMI, ST-segmentelevation myocardial infarction; and UA, unstable angina.
*LVEF was available in 2165 (87.6%) patients treated with aspirin and 699 (90.7%) patients treated with clopidogrel. Data are median (25th-75th percentiles) or number of patients (%). IPTW indicates inverse probability of treatment weighting; LAD, left anterior descending; PCI, percutaneous coronary intervention; and SMD, standardized mean difference.
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Discussion
We found that in patients who received 12-month DAPT after DES implantation without major adverse cardiac cerebrovascular events, clopidogrel monotherapy reduced the risk for the composite of cardiac death, MI, or stroke when compared with aspirin monotherapy. The association of clopidogrel monotherapy with better primary efficacy end point was consistent across various subgroups, including temporal distribution of PCI. There was no significant difference between both groups in terms of TIMI major bleeding and BARC type 3 or 5.
Establishing optimal duration of DAPT is important for balancing the risks of ischemic and bleeding complications after DES implantation. Meta-analyses have suggested that the short-term DAPT (<12 months) is associated with similar rates of ischemic events and lower rates of bleeding after DES placement than 12-month duration. 19, 20 Recently, the efficacy and safety of the long-term DAPT (>12 months) have been Data are number of patients (%). CI indicates confidence interval; BARC, Bleeding Academic Research Consortium; IPTW, inverse probability of treatment weighting; MI, myocardial infarction; and TIMI, thrombolysis in myocardial infarction. *IPTW was augmented by multiple Cox regression analyses with clinically relevant covariates included age, sex, diabetes mellitus, chronic kidney disease, previous MI, type of drug-eluting stent, year of percutaneous coronary intervention, and duration of dual-antiplatelet therapy.
†The hazard ratio for the clopidogrel monotherapy compared with the aspirin monotherapy was calculated using IPTW-weighted Cox regression models. Aspirin or Clopidogrel After DAPT evaluated in the DAPT trial 10 and Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of AspirinThrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI54) trial. 21 The 2 trials demonstrated a thrombotic benefit of long-term DAPT. However, the risk reduction of MI did not translate into mortality benefit, and an increased risk of bleeding events was observed in the 2 trials. Because some patients may have bleeding caused by extending DAPT beyond 12 months, determining the optimal treatment for patients requiring a single-antiplatelet drug, either aspirin or clopidogrel, is of paramount importance. Until now, the CAPRIE trial was only large-scale study comparing aspirin monotherapy with clopidogrel monotherapy in patients with atherosclerotic vascular disease. 11 The CAPRIE trial found that clopidogrel had a marginally significant advantage over aspirin for the prevention of stroke, MI, and vascular disease in 19 185 patients with a recent stroke, MI, or peripheral artery disease (annual event rate 5.32% versus 5.83%; P=0.043). In addition, clopidogrel was associated with a lower incidence of upper gastrointestinal discomfort and gastrointestinal hemorrhage than aspirin. Although clopidogrel had a superior efficacy and favorable safety profile, aspirin is still recommended because of marginally statistically significant inferiority and cost-effectiveness; about 200 patients would need to use clopidogrel rather than aspirin for 1 year to prevent just 1 vascular event. Clopidogrel Adjusted hazard ratios (HRs) for the primary efficacy end point in various subgroups. Interaction terms between subgroups and treatment effects on clinical outcomes were estimated in the weighted Cox regression model using the inverse probability of treatment weight (IPTW) method. A new IPTW was calculated in each subgroup and the adjusted HRs were estimated using the Cox regression models adjusted by the IPTW. ACS indicates acute coronary syndrome; BES, biolimus-eluting stent; CI, confidence interval; DM, diabetes mellitus; EES, everolimus-eluting stent; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; and ZES, zotarolimus-eluting stent.
had unattractive cost-effectiveness for secondary prevention of coronary heart disease in United States. 22 However, the cost-effectiveness studies, which were mostly performed in European countries, found that clopidogrel can be assumed to be acceptable for secondary prevention in patients with atherosclerotic vascular diseases. 23 Moreover, as clopidogrel has recently become available in a generic formation, the high cost of clopidogrel could be mitigated in current clinical settings. The CAPRIE trial was performed before the introduction of DES, and there is no study comparing aspirin monotherapy with clopidogrel monotherapy after completion of 12-month DAPT in patients who received PCI with a DES.
Our study provides hypothesis-generating evidence that clopidogrel monotherapy had more prognostic benefit than aspirin monotherapy after DAPT in patients with DES implantation. There were no significant interactions between primary efficacy end point and several subgroups regardless of age, acute coronary syndrome, diabetes, current smoking status, stroke, multivessel disease, stent type, and PCI year. The benefit of clopidogrel over aspirin is amplified in a range of highrisk subgroups from CAPRIE trial. This effect was observed in CAPRIE patients with a history of previous cardiac surgery, 24 diabetic patients, 25 and those with a remote previous history of ischemic events. 26 These benefits of clopidogrel might be because of multiple actions of a P2Y 12 receptor signaling. First, P2Y 12 receptor signaling plays a key role in platelet activation, and activated platelets trigger the coagulation cascade by inducing thrombin generation on their surface. 27 These platelet procoagulant activities can be inhibited by clopidogrel. 28 Second, when compared with aspirin, clopidogrel has potent antiplatelet effects, which target both purinergic and nonpurinergic pathways. 29 In addition, clopidogrel inhibits the binding of ADP to its platelet P2Y 12 receptor, which also plays a crucial role in ADP-mediated generation of thromboxane A2. 30, 31 Clopidogrel alone inhibits platelet thromboxane A2 activation pathway in vitro and in vivo and can decrease physiological thromboxane level, 31 and cessation of clopidogrel in patients treated with DAPT might cause a weakening of the response to aspirin. 32 Moreover, aspirin action might reduce in patients under chronic aspirin treatment caused by platelet multidrug resistance protein-4 overexpression. 33 Safety concerns on late bleeding should be considered when we select antiplatelet monotherapy. We observed no significant difference between aspirin monotherapy and clopidogrel monotherapy in terms of TIMI major bleeding including fatal bleeding or intracranial bleeding. BARC type 3 or 5 bleeding also was similar between 2 groups. This study has several limitations inherent to a retrospective analysis of observational data. First, the choice of antiplatelet agent was not randomly assigned but was selected at the discretion of the attending physician. Although we rigorously adjusted for differences in baseline characteristics using the IPTW and multivariable models, the marked differences may not be overcome and unmeasured confounders may have affected our results. In addition, because clopidogrel monotherapy were more selected at the later period, the benefits of clopidogrel monotherapy might be simply attributed to the improved technical aspects of performing PCI. Large numbers of patients in the clopidogrel group were treated with everolimus, zotarolimus, or biolimus-eluting stents, which are associated with a lower incidence of adverse clinical events than sirolimus or paclitaxel-eluting stents. 34 However, we performed multivariable Cox regression analysis that included the type of stent and PCI year, and there was no significant interaction of treatment effect on the primary efficacy end point according to the type of stent and PCI year. Second, clinical events were identified by the attending physicians, not assessed by an independent clinical events adjudication committee. In addition, statistical power of this study might be low because of low event rate. The rates of MI and stent thrombosis were low when compared with adequately powered DAPT trial, which excluded patients with adverse clinical events for at least 12 months. 10 We cannot exclude the possibility of under-reporting of clinical outcomes such as MI and stent thrombosis. In terms of interaction test with stent type, subgroup analyses reduce the sample size even more, most are underpowered. Finally, some significant results with P values close to 5% are perhaps type I errors with multiple tests. Our findings should be viewed with caution and potentially used for the purpose of generating hypotheses that may be tested in a large-scale confirmatory trial.
Conclusions
In patients receiving 12-month DAPT after DES implantation without adverse clinical outcomes, clopidogrel monotherapy reduced the risk of recurrent ischemic events with a similar risk of bleeding when compared with aspirin monotherapy. This finding may have important practical implications for determining the optimal treatment for patients requiring a single-antiplatelet drug, either aspirin or clopidogrel, for secondary prevention of ischemic events. Our findings should be further investigated through a randomized clinical trial.
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